PLATIPARP
Dr Agarwal (Huntsman Cancer Institute, University of Utah, Salt Lake City, USA) discusses key clinical trials in mCRPC covered at ASCO 2024, focusing on poly-ADP ribose polymerase inhibitors (PARPi). View transcript.
Infographic: Key insights from the mCRPC roundtable
-
English - mCRPC treatment Current advances and future horizonsPdf, 3.50 MB
-
French - Traitement du CPRCm Progrès actuels et horizons futursPdf, 2.76 MB
-
German - Behandlung des mCRPC Aktuelle Fortschritte und ein Blick in die ZukunftPdf, 2.76 MB
-
Italian - Trattamento dell’mCRPC progressi attuali e orizzonti futuriPdf, 2.76 MB
-
Spanish - Tratamiento del CPRCm avances actuales y perspectivas para el futuroPdf, 2.76 MB
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.